Milan Scheidegger is a visionary and integrative thinker with an academic background in medicine, neuroscience, philosophy, and psychiatry. He is driven by the passion to understand the nature of human existence from its molecular basis up to the level of phenomenal consciousness. As a resident physician at the Department of Psychiatry, Psychotherapy, and Psychosomatics (University of Zurich), he aims at developing „Transformational Psychotherapy“ as a novel and paradigm-changing treatment approach that advocates a shift from pharmacological substitution towards integrative transformational healthcare.
After successful completion of his MD-PhD training in functional and molecular neuroimaging at the Institute for Biomedical Engineering (ETH Zurich) he continues to research the neurobiology and pharmacology of altered states of consciousness and the potential of psychedelics such as ketamine, psilocybin, ayahuasca and DMT to facilitate therapeutic transformation. Together with Dr. Davor Kosanic he co-founded the non-profit social enterprise RECONNECT - Deep Consciousness Tools for Transformational Health Care. As a clinician he is primarily trained in cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT), acceptance and commitment therapy (ACT), compassion- and emotion-focused therapy (CFT/EFT), ego-state therapy, mindfulness-based psychotherapy, and psychedelic-assisted therapy.
Beyond empirical research, he earned an M.A. degree in History and Philosophy of Knowledge (ETH Zurich). Being deeply knowledgeable about biosemiotics, philosophy of mind, epistemology and phenomenology of consciousness, mindfulness and deep ecology, he developed a broader perspective on life. On his ethnobotanical expeditions to Mexico, Colombia and Brazil, he explored the traditional use of psychoactive plants in indigenous rituals.
He is current member of the Swiss Society for Psycholytic Therapy (SÄPT) and the MIND European Foundation for Psychedelic Science. He is former scholar of the Swiss Study Foundation and received the Young Investigators Award from the Swiss Society of Biological Psychiatry (2013).